摘要
目的检测肿瘤浸润淋巴细胞(tumor-infiltrating lymphocytes,TILs)和乳腺癌新辅助治疗疗效病理完全反应(pathological complete response,pCR)的关系及TILs在乳腺癌新辅助治疗前后的动态变化情况。方法收集2014年1月至2018年12月广州医科大学附属肿瘤医院100例乳腺癌新辅助治疗前后配对石蜡标本696块;H&E染色手工评价TILs水平;SPSS 22.0软件分析TILs对pCR的预测作用及TILs在新辅助治疗前后的动态变化。结果二元回归分析模型示总区域TILs(OR 1.182,95%CI 1.030~1.358,P=0.018)和肿瘤区域内TILs(OR 1.727,95%CI 1.137~2.622,P=0.010)具有很好的pCR预测价值。总患者中(100例),新辅助治疗前后TILs在总区域(P<0.0001)、间质区域(P<0.0001)、肿瘤内区域(P=0.057)均显著升高。结论全区域TILs、肿瘤内区域TILs可预测乳腺癌新辅助治疗pCR。新辅助治疗可促进乳腺癌患者肿瘤区域TILs免疫浸润。
Objective This study is to investigate the relationship of tumor-infiltrating lymphocytes and pathological complete response(pCR)to neoadjuvant treatment(NAT)in breast cancer,and to observe the dynamic change of TILs between pre-and post-NAT.Methods A total of 100 cases of breast cancer with 696 paraffin blocks were collected between January 2014 and December 2018 in Affiliated Cancer Hospital&Institute of Guangzhou Medical University.TILs was evaluated by pathologists on H&E sections.SPSS 22.0 was used to detect the predictive value of TILs to pCR and the dynamic change of TILs between pre-and post-NAT.Results Bivariate regression analysis indicated that Total TILs(OR 1.182,95%CI 1.030~1.358,P=0.018)and Intratumoral TILs(OR 1.727,95%CI 1.137~2.622,P=0.010)were statistically significant and independent predictors of pCR.Otherwise,the Total TILs(P<0.0001),Stromal TILs(P<0.0001)and Intratumoral region TILs(P=0.057)in pre-NAT tissue were significantly higher than those in post-NAT.Conclusions Total TILs and Stromal TILs could be predictive factors for pCR to NAT in breast cancer.Meanwhile,NAT could promote Stromal TILs in breast cancer.
作者
金田恩
黄嘉
谢至
郭伟玲
叶祉青
黄健清
梁红玲
JIN Tian-en;HUANG Jia;XIE Zhi;GUO Wei-ling;YE Zhi-qing;HUANG Jian-qing;LIANG Hong-ling(Guangzhou DAAN Clinical Laboratory Center,Guangzhou 510520,China;Guangzhou Medical University,Guangzhou 510006,China;Medical Research Center,Guangdong Provincial People's Hospital,Guangdong Lung Cancer Institute,Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer,Guangzhou 510080,China;Affiliated Cancer Hospital&Institute of Guangzhou Medical University,Guangzhou 510095,China)
出处
《循证医学》
2020年第3期174-180,共7页
The Journal of Evidence-Based Medicine
基金
广州市卫生和计划生育委员会一般引导项目资助项目(20191A011097)
广州市科学技术局一般引导项目资助项目(201904010331)。
关键词
乳腺癌
新辅助治疗
肿瘤浸润淋巴细胞
breast cancer
neoadjuvant treatment
tumor-infiltrating lymphocytes